Trial Profile
Phase I/II Study of Lenalidomide in Combination With Anti-PD-1 Monoclonal Antibody CT-011 in Patients With Relapsed/Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Pidilizumab (Primary)
- Indications Multiple myeloma; Plasmacytoma
- Focus Adverse reactions; Therapeutic Use
- 14 Nov 2022 Status changed from completed to discontinued.
- 28 May 2019 Status changed from active, no longer recruiting to completed.
- 14 Feb 2019 Planned End Date changed from 30 Jun 2018 to 31 Dec 2019.